Detalles de la búsqueda
1.
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
N Engl J Med;
388(17): 1547-1558, 2023 Apr 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-36912538
2.
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.
Lancet;
403(10442): 2416-2425, 2024 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38763153
3.
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
Lancet;
403(10442): 2405-2415, 2024 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38763154
4.
Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial.
Br J Cancer;
129(4): 706-720, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37420000
5.
Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.
Lancet;
397(10274): 581-591, 2021 02 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-33581820
6.
Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study).
BJU Int;
130(3): 370-380, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35373443
7.
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial.
Lancet;
396(10260): 1413-1421, 2020 10 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-33002429
8.
The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer.
Br J Cancer;
123(7): 1063-1070, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32669672
9.
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.
N Engl J Med;
375(15): 1415-1424, 2016 10 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-27626136
10.
Pathological upgrading in prostate cancer treated with surgery in the United Kingdom: trends and risk factors from the British Association of Urological Surgeons Radical Prostatectomy Registry.
BMC Urol;
19(1): 94, 2019 Oct 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-31623595
11.
PTEN loss and activation of K-RAS and ß-catenin cooperate to accelerate prostate tumourigenesis.
J Pathol;
243(4): 442-456, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29134654
12.
Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate-risk localised prostate cancer - results from a large contemporaneous cohort.
BJU Int;
120(5B): E59-E63, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28317247
13.
Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer.
BJU Int;
119(5): 667-675, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27753182
14.
Laparoendoscopic single-site donor nephrectomy (LESS-DN) versus standard laparoscopic donor nephrectomy.
Cochrane Database Syst Rev;
(5): CD010850, 2016 May 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-27230690
15.
Knockdown of WAVE3 impairs HGF induced migration and invasion of prostate cancer cells.
Cancer Cell Int;
15: 51, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26052252
16.
TNM clinical staging of prostate cancer: issues and solutions.
BJU Int;
123(3): 382-384, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30315677
17.
Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09).
Lancet Oncol;
14(4): 306-16, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23465742
18.
Development and Characterisation of a New Patient-Derived Xenograft Model of AR-Negative Metastatic Castration-Resistant Prostate Cancer.
Cells;
13(8)2024 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38667288
19.
Prostate transglutaminase (TGase-4, TGaseP) enhances the adhesion of prostate cancer cells to extracellular matrix, the potential role of TGase-core domain.
J Transl Med;
11: 269, 2013 Oct 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-24161123
20.
Putative prognostic epithelial-to-mesenchymal transition biomarkers for aggressive prostate cancer.
Exp Mol Pathol;
95(2): 220-6, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23933194